Cimicoxib for the Treatment of Major Depression (SECIM)

Mise à jour : Il y a 4 ans
Référence : NCT00510822

Femme et Homme

Extrait

This multicenter study aims to investigate the safety and efficacy of cimicoxib, a selective COX-2 inhibitor, in combination with sertraline compared to sertraline combined with placebo in patients with major depression. This clinical study is based on the assumption that adjunctive treatment of major depression with a COX-2 inhibitor may be beneficial.


Critère d'inclusion

  • Major depression

Liens